Monthly Archives: October 2018

Guidelines recommend withholding clopidogrel 7 days before polypectomy to reduce bleeding risk, but these were written based on limited evidence. We investigated whether uninterrupted clopidogrel therapy increases the risk of delayed post-polypectomy b… Continue reading →

The major risk factors for hepatocellular carcinoma (HCC) in a contemporary clinical practice is becoming increasingly related to post sustained virological response hepatitis C, suppressed hepatitis B virus on treatment, alcoholic and non-alcoholic fa… Continue reading →

Direct-acting antiviral (DAA) regimens are safe and effective at eradicating hepatitis C virus (HCV) infection. Unfortunately, DAAs remain expensive, so treatment of all HCV-infected patients would substantially affect healthcare costs. It is therefore… Continue reading →

Fewer than 1% of chronic hepatitis B virus (HBV) infections per year are cured with antiviral treatment. This creates a need for long-term treatment, which poses challenges for patients and health systems. Since cure is accompanied by recovery of antiv… Continue reading →

To make the credentialing and privileging process more intuitive and streamlined for clinicians, Vanderbilt University Medical Center is implementing a new credentialing software suite known as “Cactus.” Continue reading →

Critically ill patients are not benefiting from antipsychotic medications that have been used to treat delirium in intensive care units (ICUs) for more than four decades, according to a study released today in the New England Journal of Medicine. Continue reading →

Zombies! The Grim Reaper! Ghosts! A pineapple jack-o-lantern! Continue reading →